SALT LAKE CITY, Utah, USA, November 18, 2026
Recursion Pharmaceuticals (NASDAQ: RXRX) has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 clinical trial of REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The planned trial incorporates a composite event-free survival endpoint that includes the excision of adenomas measuring 10 mm or larger across the upper and lower gastrointestinal (GI) tract, marking a significant regulatory milestone in the development of a potential pharmacological treatment for a disease with no approved drug therapies.
FDA Aligns on Clinically Meaningful Phase 3 Endpoint
The Phase 3 trial will evaluate REC-4881 at a 4 mg dose in approximately 200 adults with FAP who have previously undergone colectomy or proctocolectomy. The randomized, double-blind, placebo-controlled, event-driven study will assess event-free survival from randomization until the occurrence of a qualifying event, including excision of an adenoma measuring 10 mm or larger in either the upper or lower GI tract, FAP-related surgery meeting prespecified criteria, development of high-grade dysplasia or cancer, or death from any cause. The FDA alignment also includes modified Spigelman stage progression and total polyp burden as secondary endpoints, with a prespecified interim analysis planned. Adenomas measuring at least 10 mm are associated with an increased risk of high-grade dysplasia and cancer and frequently require removal through advanced endoscopic procedures. Their excision can involve risks such as bleeding, intestinal perforation, incomplete resection and repeat intervention. By incorporating qualifying adenoma removal into the primary endpoint, the study is designed to capture clinically consequential disease progression and interventions that affect patients throughout their treatment journey.
REC-4881 Advances Following Phase 2 TUPELO Results
REC-4881 is an investigational oral allosteric MEK1/2 inhibitor designed to address the Wnt/β-catenin and MAPK pathways. The candidate was identified through unbiased phenotypic screening using Recursion’s AI foundation models, highlighting the role of artificial intelligence in discovering potential therapies for rare and complex diseases. REC-4881 has received FDA Orphan Drug and Fast Track designations for FAP and is currently being evaluated in the Phase 1b/2 TUPELO trial (NCT05552755) in adults following colectomy. Updated TUPELO data presented at CGA-IGC on November 2, 2026, demonstrated a 47% median reduction in total polyp burden after 12 weeks of treatment with REC-4881 4 mg once daily. Approximately one-third of patients achieved polyp burden reductions of 65% or greater, with activity observed across the GI tract. Half of the patients improved by at least one Spigelman stage, while 85% of evaluable patients remained below baseline polyp burden 12 weeks after treatment discontinuation. No new safety signals were observed in the reported data. These findings supported Recursion’s decision to advance the candidate toward registrational Phase 3 development.
FAP Unmet Need and Expected Trial Initiation in 2027
Familial adenomatous polyposis (FAP) is a rare inherited disorder caused by mutations in the APC gene and is characterized by the development of numerous colorectal and gastrointestinal adenomas. Without preventive surgery, the lifetime risk of colorectal cancer approaches 100%. Although colectomy significantly reduces colorectal cancer risk, it does not eliminate disease progression, as polyps can continue to develop in the remaining rectum, ileal pouch and upper GI tract. Patients often require lifelong endoscopic surveillance, repeated polyp removal and, in some cases, additional major surgeries. Recursion estimates that FAP affects more than 50,000 patients across the United States and EU5 markets, with a substantial unmet need for treatments that could reduce polyp progression and the burden of repeated interventions. The registrational Phase 3 trial of REC-4881 is expected to begin in the second half of 2027. If successful, the program could advance a potential first-in-class oral treatment option for patients living with FAP, while demonstrating how AI-enabled drug discovery can translate into clinical development programs targeting underserved rare disease populations.
Source: Recursion Pharmaceuticals press release



